Celcuity (CELC) reported a Q3 adjusted loss late Wednesday of $0.78 per diluted share, wider than a loss of $0.65 a year earlier.

Three analysts expected a loss of $0.96 in a FactSet poll.

The clinical-stage biotechnology company said it has funds to run its operations through 2027.